US Jury Finds Takeda Delayed Generic Constipation Drug in Antitrust Scheme

• The verdict holds Takeda liable for $885 million in damages across multiple affected parties including pharmacies, insurers, and retailers
• The case centered on allegations that Takeda engaged in an antitrust scheme to delay generic competition for Amitiza, its anti-constipation medication
• The jury's finding represents a significant legal loss for the Japanese pharmaceutical company in a U.S. antitrust case

Summary: US Jury Finds Takeda Delayed Generic Constipation Drug in Antitrust Scheme

A U.S. jury ruled on Monday, May 18, that Takeda Pharmaceutical engaged in anticompetitive practices by delaying the release of a generic version of Amitiza, its anti-constipation drug. The verdict found the Japanese pharmaceutical company liable for approximately $885 million in damages.

Key Details:

The damages awarded will compensate pharmacies, insurers, retailers, and other affected parties who suffered financial losses due to Takeda's scheme to postpone generic competition for Amitiza.

Company Impact:

Takeda Pharmaceutical, one of Japan's largest pharmaceutical companies, faces significant financial liability from this antitrust ruling. The case represents a substantial legal setback for the drugmaker and highlights ongoing scrutiny of pharmaceutical companies' practices regarding generic drug market entry.

Market Implications:

This verdict reinforces regulatory and legal pressure on pharmaceutical companies that employ strategies to delay generic competition, often called "pay-for-delay" or similar anticompetitive schemes. The substantial damages award may serve as a deterrent for similar practices across the industry and could impact Takeda's financial performance and reputation.

The ruling adds to growing legal challenges facing major pharmaceutical companies over market manipulation tactics that keep drug prices artificially high by blocking generic alternatives. Investors should monitor potential appeals and whether this decision influences other pending antitrust cases in the pharmaceutical sector.

The case was decided in Boston, though specific details about the anticompetitive scheme's mechanics were not disclosed in the brief report.